Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Ovarian Neoplasms 56Fallopian Tube Neoplasms 25Breast Neoplasms 18Neoplasms 14Carcinoma, Ovarian Epithelial 14Multiple Myeloma 9Neoplasm Metastasis 7Triple Negative Breast Neoplasms 3Recurrence 3Peritoneal Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Cancer Recurrent 2Liver Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vaccinia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

pembrolizumab 180Cisplatin 44Paclitaxel 41Carboplatin 41lenvatinib 31Docetaxel 22Pemetrexed 20Fluorouracil 19Capecitabine 16Gemcitabine 15Saline Solution 13Oxaliplatin 13Albumin-Bound Paclitaxel 10epacadostat 9130-nm albumin-bound paclitaxel 9Leucovorin 8Cetuximab 8olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6belzutifan 5Dexamethasone 5enzalutamide 4trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × liposomal doxorubicin × Clear all
NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
340 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡